Listen
CAELYX (pegylated liposomal doxorubicin), antineoplastic
ONCOLOGY - Update
Opinions on drugs -
Posted on
Jun 10 2016
Reason for request
Re-assessment of the actual benefit and the improvement in actual benefit
No clinical benefit demonstrated by comparison with liposomal daunorubicin, in patients at an advanced stage of the HIV infection with extensive mucocutaneous or visceral Kaposi’s sarcoma who have an incomplete response to antiretroviral treatment.
- CAELYX has Marketing Authorisation in the treatment of AIDS-related Kaposi’s sarcoma (KS) in patients with low CD4 counts and extensive mucocutaneous or visceral disease.
- Its effectiveness has been evaluated in studies with low levels of evidence and without comparison to liposomal daunorubicin.
- The role of CAELYX is from now on limited in immunocompromised patients with Kaposi’s sarcoma.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
